Fabien Depis
Founder & Chief Executive Officer TregShield Bio
Fabien Depis, Ph.D. is Founder and CEO of TregShield Bio, developing next-generation organ-selective antibodies engineered to be systemically inactive and conditionally activated within I&I diseased tissues. With over 17 years advancing Treg-targeted therapies, he is an expert in Treg modulation across cancer and autoimmunity. He served as Program Leader and Co-Inventor of the CCR8-targeted tumor Treg antibody GS-1811 at Jounce Therapeutics, now in Phase 1 immuno-oncology development with Gilead. His experience spans TNFR2 at Merrimack, Foralumab (NovImmune), CEL383 (Celsius), DT101 (Dualyx), and Treg cell therapies as Head of Discovery at GentiBio. He trained at Harvard Medical School (Mathis/Benoist) and chairs the Treg Summit (2023-2025).
Seminars